Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesThiogenesis Therapeutics Corp.

Thiogenesis Therapeutics Corp.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.63 CAD 0.00(0%)
Last update at 2026-11-04T14:54:00Z
VOLUME
12000
Market Cap
31.62M

Momentum Score

…

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.63
Low
0.64
High
52 Week Price Range
0.44
Low
0.88
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Thiogenesis Therapeutics Corp. is a publicly listed company on the TSX Venture Exchange; limited public information is available about its specific operations or product pipeline. If the company is an early‑stage life sciences business, long‑term growth may depend on successful research and development, regulatory milestones, intellectual property protection and strategic partnerships, which could make it of interest to investors seeking higher‑risk biotech exposure.
Primary investment risks include development and regulatory uncertainty, likely need for external financing with potential shareholder dilution, low trading liquidity on the TSXV and concentrated operational or management risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.63
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-216.52%
Net Debt
0.30M
ROCE
-104.49%
Diluted EPS TTM
-0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -3.15M -5.06M -3.92M -0.22M -0.09M
Net income -3.15M -5.06M -3.92M -0.22M -0.09M
Selling general administrative 1.36M 1.04M 0.93M 0.22M 0.09M
Ebitda - - - -0.22M -0.09M
Operating income -3.58M -5.21M -1.97M -0.22M -0.09M
Interest expense - 0.00M 0.00M 0.00M 0.00M
Interest income 0.20M 0.17M 0.01M 0.00M 0.00M
Net interest income 0.20M 0.17M 0.00M 0.00M -0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 3.58M 5.21M 1.97M 0.22M 0.09M
Total other income expense net 0.23M -0.03M -1.95M - -
Net income from continuing ops -3.15M -5.06M -3.92M -0.22M -0.09M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 3.98M 7.24M 6.29M 3.43M 0.15M
Total liab 0.56M 1.71M 0.31M 3.49M 0.06M
Total stockholder equity 3.43M 5.53M 5.98M -0.06M 0.08M
Capital stock 16.14M 15.01M 11.13M 0.30M 0.27M
Retained earnings -14.28M -11.14M -6.18M -0.45M -0.23M
Cash 3.85M 7.08M 6.20M - 0.02M
Total current liabilities 0.56M 1.71M 0.31M 3.49M 0.06M
Net debt - - - - 0.30M
Short long term debt - - - - 0.32M
Total current assets 3.98M 7.24M 6.29M 3.43M 0.15M
Net receivables 0.00M 0.01M 0.01M - 0.00M
Accounts payable - - - - 0.03M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - 0.00M 0.11M - -
Net borrowings - 0.00M -0.18M - -
Total cash from financing activities 0.72M 4.12M 8.13M 3.33M 0.00M
Net income -3.15M -5.06M -3.92M -0.22M -0.09M
Change in cash -3.23M 0.88M 6.13M 3.26M -0.04M
Begin period cash flow 7.08M 6.20M 3.41M 0.15M 0.18M
End period cash flow 3.85M 7.08M 6.20M 3.41M 0.15M
Total cash from operating activities -3.92M -3.25M -2.09M -0.07M -0.04M
Issuance of capital stock 0.00M 4.12M 4.88M - 0.00M
Change to account receivables -0.00M -0.06M -0.01M - 0.00M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -1.12M 1.33M -0.57M 0.16M 0.06M
Stock based compensation 0.35M 0.48M 0.52M - 0.03M
Other non cash items - - 1.94M - 0.00M
Free cash flow -3.92M -3.25M -2.09M -0.07M -0.04M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 -58.16
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 -
NRX
NurExone Biologic Inc.		 -0.03
5.00%		 0.47 - 6.90 - 15.26 -7.24
MIR
MedMira Inc		 -0.01
9.09%		 0.05 - - 223.37 - -80.03
ARCH
Arch Biopartners Inc		 -0.03
3.41%		 0.85 - - 197.68 6211.54 6970.51

Profile*

Thiogenesis Therapeutics Corp.

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.

4 King Street West, Toronto, ON, Canada, M5H 1B6

888-223-9165

https://www.thiogenesis.com

Name Title Year Born
Dr. Patrice P. Rioux M.D., Ph.D. CEO & Director 1951
Ms. Mary Jo Bagger Consultant for Clinical Operations NA
Mr. Brook G. Riggins C.F.A. CFO, Sec. & Director 1966
Dr. Patrice P. Rioux M.D., Ph.D. Co-Founder, CEO & Director 1951
Mr. Brook G. Riggins C.F.A. CFO, Secretary & Director 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…